Is X4 Pharmaceuticals Inc (XFOR) overvalued? · rev $6.5M
X4 Pharmaceuticals Inc (XFOR) is a biotechnology company listed on NASDAQ.
This page asks whether X4 Pharmaceuticals Inc (XFOR) looks expensive on cached numbers — not a short thesis.
Latest reported XFOR revenue for 2025-12-31 was $6.5M. Net income was -$79.2M. Revenue was up 154.2% from 2024-12-31 to 2025-12-31. XFOR currently screens at market cap $382.0M.
XFOR currently screens at market cap $382.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next XFOR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the XFOR stock page for the full model, not this heading.
Not investment advice.